Yahoo
    NYSE American - Delayed Quote USD

    Oragenics, Inc. (OGEN)

    0.3702 -0.0038 (-1.02%)
    At close: 4:00:00 PM EST
    0.3702 0.0000 (0.00%)
    After hours: 5:00:57 PM EST
    Loading Chart for OGEN
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

    Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
    GlobeNewswire 1mo ago
    Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

    Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
    GlobeNewswire 2mo ago
    Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

    Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
    GlobeNewswire 3mo ago
    ORAGENICS PROVIDES INVESTOR UPDATE

    ORAGENICS PROVIDES INVESTOR UPDATE
    GlobeNewswire 5mo ago
    Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

    Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
    GlobeNewswire 5mo ago
    Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

    Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
    GlobeNewswire 5mo ago
    Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

    Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
    GlobeNewswire 6mo ago
    Sidoti Events, LLC's May Micro-Cap Virtual Conference

    Sidoti Events, LLC's May Micro-Cap Virtual Conference
    ACCESS Newswire 5mo ago
    Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

    Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
    GlobeNewswire 5mo ago
    Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

    Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
    GlobeNewswire 7mo ago
    Oragenics partners with Duck Flats Pharma to support FDA IND trial design

    Oragenics partners with Duck Flats Pharma to support FDA IND trial design
    TipRanks 8mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: